Medicare Coverage Analysis for Clinical Trials

A Medicare Coverage Analysis (MCA) is the billing-compliance review every clinical trial with billable patient-care items must complete before it opens to enrollment. It goes through a study protocol procedure by procedure and assigns each visit, test, and intervention to exactly one payer — Medicare (or another third-party payer), the trial sponsor, or the patient — based on the routine-costs framework in CMS National Coverage Determination (NCD) 310.1, “Routine Costs in Clinical Trials”. The output is a document usually called a billing grid (or coverage analysis grid, billing calendar), and it is the artifact an institution’s billing systems are actually built to follow — not the protocol, and not the informed consent form.

This guide walks through what an MCA determines, the three-part regulatory test behind it, how the process actually runs at an academic medical center, who is involved, and what happens when it is skipped, incomplete, or not kept current. It is a companion to two related CASRAI guides: Medicare Coverage Determinations: NCD vs LCD Explained, which covers the regulatory mechanism an MCA is built against, and False Claims Act Liability in Clinical Trial Billing, which covers the enforcement consequences when a coverage analysis fails or isn’t followed.

What an MCA actually determines

Every billable item or service in a clinical trial protocol falls into one of three payer categories:

Routine costs, Medicare/insurer-billable — items and services a patient would have received as part of standard medical care regardless of the trial (e.g., a follow-up office visit, a standard-of-care scan, management of the underlying condition), which Medicare covers under NCD 310.1 when the trial qualifies.
Research costs, sponsor-billable — items and services performed only because the protocol requires them: the investigational drug or device itself, extra research-only blood draws, protocol-mandated visits beyond the standard-of-care schedule, and study-specific procedures with no clinical indication outside the trial. Medicare does not pay for these; the sponsor does, per the clinical trial agreement budget.
Patient responsibility — standard copayment, coinsurance, or deductible amounts that would apply to a routine-cost item under the patient’s normal coverage, unless the sponsor has separately agreed to cover them.

An MCA is not optional paperwork layered on top of billing — it is the mechanism that keeps an institution from billing the same service to two payers at once, which is the fact pattern behind essentially every clinical-trial-billing False Claims Act settlement on record (see False Claims Act Liability in Clinical Trial Billing for two real, publicly documented cases). Any trial with billable patient-care services generally requires an MCA before activation, even when no Medicare beneficiaries are currently expected to enroll — enrollment criteria change, and a trial without a completed coverage analysis has no documented basis for billing anyone correctly.

The three-part regulatory test

A Medicare Coverage Analysis works through three sequential questions for a protocol, each grounded in NCD 310.1 and the broader Medicare coverage framework:

Does the trial qualify? The clinical trial must meet NCD 310.1’s definition of a Qualifying Clinical Trial — its subject or purpose must fall within a Medicare benefit category, it must have genuine therapeutic intent (rather than testing toxicity or pathophysiology exclusively in healthy subjects), and, for therapeutic trials, it must enroll patients with the diagnosis under study. A trial is automatically deemed to satisfy these criteria if it is funded by NIH, CDC, AHRQ, CMS, the Department of Defense, or the VA, or conducted under an FDA Investigational New Drug (IND) application (or an IND-exempt drug trial under 21 CFR 312.2(b)(1)). Trials that don’t meet any deeming criterion still need a documented case-by-case qualifying analysis against the same three-part test.
Which items are routine costs? For a qualifying trial, each protocol-required item or service is checked against the routine-costs definition: would it normally be furnished to this patient as standard care whether or not the trial existed, or is it otherwise a Medicare-covered item or service that happens to be provided in either arm of the trial? Items that fail this test — most centrally the investigational item or service itself — are excluded from routine-cost coverage and fall to the sponsor.
Do other Medicare coverage rules apply or limit coverage? A routine cost still has to clear the ordinary Medicare coverage rules that would apply outside a trial — a service-specific NCD, a Local Coverage Determination (LCD) from the institution’s Medicare Administrative Contractor, frequency limits, or a statutory exclusion. A service-specific NCD or LCD takes priority over the general NCD 310.1 routine-costs framework where the two overlap. See Medicare Coverage Determinations: NCD vs LCD Explained for how NCDs and LCDs are issued and how conflicts between them resolve.

Coverage decisions have to be applied consistently across the entire enrolled population for a given protocol — if an item is determined routine for one patient’s visit, it must be treated identically for every patient receiving that same protocol-required item, not decided ad hoc claim by claim.

The MCA process step by step

While specific workflows vary by institution, tool, and Clinical Trials Office (CTO) structure, the process generally runs through the same sequence:

Protocol intake. The coverage analysis team (typically within the CTO or a dedicated research billing compliance office) receives the full protocol, schedule of assessments/visit calendar, and draft Clinical Trial Agreement (CTA) budget, usually triggered automatically once a study is submitted for IRB review or budget negotiation.
Qualifying determination. The team applies the first part of the three-part test above to establish whether the trial is a Qualifying Clinical Trial for Medicare routine-cost purposes, documenting which deeming criterion applies (or completing the case-by-case analysis if none does).
Item-by-item routine cost analysis. Every visit, procedure, lab draw, and imaging study on the schedule of assessments is individually classified as routine cost, research cost, or standard-of-care-but-research-timed, cross-referenced against applicable service-specific NCDs/LCDs.
Billing grid construction. The classifications are compiled into a billing grid (also called a coverage analysis grid or billing calendar) mapping every protocol event to its payer, visit by visit. This becomes the working document the institution’s research billing and hospital/professional billing systems are built against.
Budget and consent reconciliation. The billing grid is checked against the sponsor budget under negotiation (so the sponsor is billed for every item the MCA assigns to research costs, and only those) and against the informed consent form’s billing disclosure language, which is required to tell participants what costs they, their insurer, or Medicare may be responsible for.
Billing system configuration. Once finalized, the billing grid is loaded into the institution’s clinical trial management system (CTMS) and/or hospital billing system (e.g., Epic research billing) so that claims generated for trial participants route to the correct payer automatically, including the claim-level and line-item flags Medicare requires for a qualifying trial — see the Condition Code 30 dictionary entry for how institutional claims are flagged, alongside the HCPCS Q0/Q1 modifiers applied at the line-item level.
Re-analysis on amendment. Any protocol amendment that adds, removes, or changes the timing of a billable procedure requires the coverage analysis and billing grid to be updated before the change takes effect operationally — an MCA is a living document tied to the current version of the protocol, not a one-time deliverable completed at activation and then left alone.

Who’s involved

An MCA is rarely completed by one person or one office in isolation:

Research billing compliance / coverage analysis staff (often housed in the CTO) build and maintain the coverage analysis and billing grid, and are usually the ones who catch a fact pattern before it becomes a billing error.
The principal investigator and study team confirm the clinical accuracy of what’s standard-of-care versus protocol-driven for the population being studied — a determination the billing office alone cannot make without clinical input.
Budget negotiators use the finalized billing grid to build or validate the sponsor budget, since every item assigned to research costs in the MCA should have a corresponding line in the CTA budget (see The Cost of Running a Clinical Trial for how coverage analysis feeds into overall trial budgeting).
The IRB reviews the informed consent form’s billing-disclosure language, which should be consistent with the completed coverage analysis, and many institutions use an IRB billing-risk flag as the trigger that routes a new protocol to the coverage analysis team in the first place.
Hospital/professional billing and revenue-cycle staff operationalize the billing grid at the claims level once it’s finalized, applying the payer assignment, condition codes, and modifiers it specifies to each claim as it’s generated.

What happens when the MCA is missing, wrong, or ignored

An out-of-date, incomplete, or never-implemented coverage analysis is one of the most common root causes behind clinical-trial Medicare billing errors, because it breaks the one mechanism meant to keep the same charge from reaching two payers. When that happens, the practical and legal consequences can include: repayment obligations to Medicare, loss of billing privileges for a study or, in serious cases, broader CMS scrutiny, and — where the pattern involves systematically billing Medicare for costs the sponsor already agreed to cover — False Claims Act exposure, including qui tam suits brought by employees (research billing coordinators and revenue-cycle staff are common relators, since they’re the ones reconciling charges against the coverage analysis in the ordinary course of their work). See False Claims Act Liability in Clinical Trial Billing for the full enforcement picture, including two real Department of Justice settlements that turned entirely on this fact pattern.

Frequently asked questions

Does every clinical trial need a Medicare Coverage Analysis?

Any trial with billable patient-care items generally needs one, even if no Medicare beneficiaries are currently expected to enroll. Enrollment can change over the life of a study, and without a completed coverage analysis there’s no documented basis for billing any payer correctly from day one.

Who performs the coverage analysis at a research institution?

Typically a dedicated research billing compliance function within the Clinical Trials Office, working with hospital or professional billing compliance staff, the principal investigator, and (for the budget side) the office negotiating the clinical trial agreement.

What’s the difference between a coverage analysis and a billing grid?

The coverage analysis is the review process and its underlying determinations; the billing grid (or coverage analysis grid) is the resulting document — a visit-by-visit map of every protocol item to its payer — that billing systems are actually configured against.

Does the MCA determine what goes in the informed consent form?

It should inform it. Consent forms are generally required to disclose what costs a participant, their insurer, or Medicare may be responsible for, and that disclosure should match the payer assignments the coverage analysis has already made — inconsistency between the two is a common compliance gap institutions specifically check for during consent review.

Does a completed MCA need to be updated after the trial opens?

Yes. Any protocol amendment that changes a billable procedure, visit, or its timing requires the coverage analysis and billing grid to be revised before the change takes effect operationally — it isn’t a one-time deliverable.

How is a Medicare Coverage Analysis different from an NCD or LCD?

An NCD (National Coverage Determination) and LCD (Local Coverage Determination) are the regulatory instruments CMS and its Medicare Administrative Contractors issue to decide whether an item or service is covered at all. A Medicare Coverage Analysis is the institution-level process that applies those coverage rules — along with NCD 310.1’s qualifying-trial and routine-cost tests — to one specific protocol’s line items. See Medicare Coverage Determinations: NCD vs LCD Explained for the NCD/LCD mechanism itself.

Medicare Coverage Analysis for Clinical Trials: The Complete Process